论文部分内容阅读
背景:肝细胞癌在世界范围内居恶性肿瘤的第五位,通常是由肝硬化发展而来。区分两者的生物标记物是至关重要而又有限的。方法:在本研究中,采用超高效液相色谱质谱(UPLC-MS)-基于代谢组学的方法来描述82例肝癌患者,48例肝硬化患者和90例健康对照者之间血清代谢产物的特征,并比较了UPLC-MS轮廓和甲胎蛋白水平在肝癌诊断中的准确性。结果:通过多元数据和受试者工作特征(ROC)曲线分析,代谢轮廓分析不仅可以区分患者与健康对照组,并且对于肝硬化和肝癌患者之间的区别有100%的敏感性和特异性。在肝癌患者中有13种潜在生物标记物被鉴定并被认为对关键代谢途径有显著干扰,比如有机酸、磷脂类、脂肪酸、胆汁
Background: Hepatocellular carcinoma is the fifth most common malignancy in the world and is usually developed from cirrhosis. The distinction between the two biomarkers is crucial and limited. METHODS: In this study, UPLC-MS-based metabonomics was used to characterize serum metabolites in 82 HCC patients, 48 cirrhotic patients and 90 healthy controls Features, and compared the UPLC-MS profile and alpha-fetoprotein levels in the diagnosis of liver cancer accuracy. RESULTS: By multivariate and receiver-operator characteristic (ROC) curve analysis, metabolic profiling not only distinguished patients from healthy controls, but also had 100% sensitivity and specificity for the difference between patients with cirrhosis and liver cancer. Thirteen potential biomarkers were identified in liver cancer patients and were considered to have significant interference with key metabolic pathways such as organic acids, phospholipids, fatty acids, bile